The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Links

 

Gene Review

CHAF1A  -  chromatin assembly factor 1, subunit A (p150)

Homo sapiens

Synonyms: CAF, CAF-1, CAF-1 subunit A, CAF-I 150 kDa subunit, CAF-I p150, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of CHAF1A

  • BACKGROUND AND PURPOSE: The Caf1 secretion pathway of Yersinia pestis is one of the most well-characterized export machineries [1].
  • CONCLUSION: These results suggested that the recombinant hEGF was successfully secreted through the inner membrane of cells into the periplasm and then through the outer membrane into the medium via the action of the signal peptide of Y. pestis Caf1 in E. coli [1].
  • Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma [2].
  • The results of this study suggest that CD8+ cells, as well as CAF, arrest HIV replication at the level of viral transcription [3].
  • CAF in metastatic breast cancer: standard therapy or another effective regimen [4]?
 

High impact information on CHAF1A

 

Chemical compound and disease context of CHAF1A

 

Biological context of CHAF1A

 

Anatomical context of CHAF1A

  • We show, using both immunofluorescence and Western blot analysis, that the expression of both CAF-1 large subunits, p150 and p60, is massively down-regulated during quiescence in several cell lines [14].
  • Plasma samples from patients with medullary thyroid carcinoma were gel filtered on columns of Bio-Gel P-150, and the immunoreactivity in column effuent fractions was measured with both assays [16].
  • This antiviral response, mediated by a novel CD8+ T-cell antiviral factor (CAF), occurs soon after infection and is maintained in asymptomatic individuals [17].
  • HL60 cells exhibiting a 140-fold increase in resistance to vincristine contain three surface membrane proteins with molecular weights of 210,000 (P210), 180,000 (P180), and 150,000 (P150) which are highly phosphorylated in vivo and in an in vitro system in the presence of Mn2+ and [gamma-32P]ATP [18].
  • CONCLUSION: RhuGM-CSF administered once daily at the 250-micrograms/m2/d level is well tolerated and effective in shortening the duration of the neutrophil nadir by 2 or more days after CAF therapy [19].
 

Associations of CHAF1A with chemical compounds

  • CAF-1 prepared from repair-proficient quiescent cells after induction by bleocin mediates nucleosome assembly in vitro [13].
  • Strains bearing deletions in either CCR4 or CAF1/POP2, which encode components of the cytoplasmic mRNA deadenylase complex, were particularly sensitive to HU [20].
  • In attempts to identify CAF, we discovered that certain protease inhibitors, particularly leupeptin, can block, by up to 95%, the anti-HIV activity in CD8+ cell culture fluids as well as inhibit CNAR [21].
  • Inactivation of either cyclic AMP response element binding protein (CREB)-binding protein (CBP), members of the p160 family of coactivators, or the CBP-associated factor (p/CAF) by nuclear antibody microinjection prevents NF-kappaB-dependent transactivation [22].
  • However, the utility of this assay in node-positive patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil (CAF) has not been well studied [10].
 

Other interactions of CHAF1A

  • As aberrant expression of the four proteins was not found in brains of patients with AD, decreased CAF and C21orf2 can be considered specific for DS [23].
  • Regulation of PCNA and CAF-1 expression by the two tuberous sclerosis gene products [24].
  • Fractionation of the crude venom on DEAE-Sepharose, followed by gel filtration on Bio-Gel P-150 and chromatography on CM-Sepharose, yielded an alpha-proteinase preparation which showed a single band on disc and sodium dodecyl sulfate-polyacrylamide gel electrophoresis and had an activity on casein approximately twice that previously reported [25].
  • Arginase was purified from Vigna catjang cotyledons and buffalo liver by chromatographic separations using Bio-Gel P-150, DEAE-cellulose and arginine AH Sepharose 4B affinity columns [26].
 

Analytical, diagnostic and therapeutic context of CHAF1A

  • Regulation of CAF-1 expression is partly controlled at the RNA level, as shown by quantitative reverse transcription-PCR and Northern blot experiments [14].
  • To identify the structural differences between CRS2 and bacterial PTHs responsible for CRS2's gains of CAF binding and intron splicing functions, we determined the structure of CRS2 by X-ray crystallography [15].
  • This CD8+ cell noncytotoxic antiviral response (CNAR), observed by coculture of CD8+ cells with infected CD4+ cells, is associated with secretion of a CD8+ cell antiviral factor (CAF) [21].
  • Only 13% of the CAF patients had a complete response during the first six months of chemotherapy, and this was not significantly different from the complete response rate on CMFP [27].
  • The primary end points were time to recurrence (TTR), disease-free survival (DFS), and overall survival (OS) for CAF-Z versus CAF, and CAF-ZT versus CAF-Z [28].

References

  1. Secretion of biologically active human epidermal growth factor from Escherichia coli using Yersinia pestis Caf1 signal peptide. Liu, Y.L., Huang, L.M., Lin, W.P., Tsai, C.C., Lin, T.S., Hu, Y.H., Chen, H.S., Han, J.M., Wang, H.J., Liu, Y.T. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. (2006) [Pubmed]
  2. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Neijt, J.P., ten Bokkel Huinink, W.W., van der Burg, M.E., van Oosterom, A.T., Vriesendorp, R., Kooyman, C.D., van Lindert, A.C., Hamerlynck, J.V., van Lent, M., van Houwelingen, J.C. Lancet (1984) [Pubmed]
  3. CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Mackewicz, C.E., Blackbourn, D.J., Levy, J.A. Proc. Natl. Acad. Sci. U.S.A. (1995) [Pubmed]
  4. CAF in metastatic breast cancer: standard therapy or another effective regimen? Hayes, D.F., Henderson, I.C. J. Clin. Oncol. (1987) [Pubmed]
  5. Replication-dependent marking of DNA by PCNA facilitates CAF-1-coupled inheritance of chromatin. Shibahara, K., Stillman, B. Cell (1999) [Pubmed]
  6. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Konopka, J.B., Watanabe, S.M., Witte, O.N. Cell (1984) [Pubmed]
  7. Heterochromatin dynamics in mouse cells: interaction between chromatin assembly factor 1 and HP1 proteins. Murzina, N., Verreault, A., Laue, E., Stillman, B. Mol. Cell (1999) [Pubmed]
  8. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. Parnes, H.L., Cirrincione, C., Aisner, J., Berry, D.A., Allen, S.L., Abrams, J., Chuang, E., Cooper, M.R., Perry, M.C., Duggan, D.B., Szatrowski, T.P., Henderson, I.C., Norton, L. J. Clin. Oncol. (2003) [Pubmed]
  9. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. Rosner, G.L., Hargis, J.B., Hollis, D.R., Budman, D.R., Weiss, R.B., Henderson, I.C., Schilsky, R.L. J. Clin. Oncol. (1996) [Pubmed]
  10. Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869. Guidi, A.J., Berry, D.A., Broadwater, G., Helmchen, B., Bleiweiss, I.J., Budman, D.R., Henderson, I.C., Norton, L., Hayes, D.F. J. Clin. Oncol. (2002) [Pubmed]
  11. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. Peters, W.P., Ross, M., Vredenburgh, J.J., Meisenberg, B., Marks, L.B., Winer, E., Kurtzberg, J., Bast, R.C., Jones, R., Shpall, E. J. Clin. Oncol. (1993) [Pubmed]
  12. A CAF-1-PCNA-mediated chromatin assembly pathway triggered by sensing DNA damage. Moggs, J.G., Grandi, P., Quivy, J.P., Jónsson, Z.O., Hübscher, U., Becker, P.B., Almouzni, G. Mol. Cell. Biol. (2000) [Pubmed]
  13. Induction of CAF-1 expression in response to DNA strand breaks in quiescent human cells. Nabatiyan, A., Szüts, D., Krude, T. Mol. Cell. Biol. (2006) [Pubmed]
  14. Chromatin assembly factor-1, a marker of clinical value to distinguish quiescent from proliferating cells. Polo, S.E., Theocharis, S.E., Klijanienko, J., Savignoni, A., Asselain, B., Vielh, P., Almouzni, G. Cancer Res. (2004) [Pubmed]
  15. Structural analysis of the group II intron splicing factor CRS2 yields insights into its protein and RNA interaction surfaces. Ostheimer, G.J., Hadjivassiliou, H., Hadjivasiliou, H., Kloer, D.P., Barkan, A., Matthews, B.W. J. Mol. Biol. (2005) [Pubmed]
  16. Immunochemical heterogeneity of calcitonin in plasma of patients with medullary thryoid carcinoma. Sizemore, G.W., Hpeath, H., Larson, J.M. J. Clin. Invest. (1975) [Pubmed]
  17. Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells. Levy, J.A., Mackewicz, C.E., Barker, E. Immunol. Today (1996) [Pubmed]
  18. Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. McGrath, T., Center, M.S. Cancer Res. (1988) [Pubmed]
  19. Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil. O'Reilly, S.E., Gelmon, K.A., Onetto, N., Parente, J., Rubinger, M., Page, R.A., Plenderleith, I.H. J. Clin. Oncol. (1993) [Pubmed]
  20. Ccr4 contributes to tolerance of replication stress through control of CRT1 mRNA poly(A) tail length. Woolstencroft, R.N., Beilharz, T.H., Cook, M.A., Preiss, T., Durocher, D., Tyers, M. J. Cell. Sci. (2006) [Pubmed]
  21. The CD8+ cell noncytotoxic anti-HIV response can be blocked by protease inhibitors. Mackewicz, C.E., Craik, C.S., Levy, J.A. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  22. Transcriptional activation by NF-kappaB requires multiple coactivators. Sheppard, K.A., Rose, D.W., Haque, Z.K., Kurokawa, R., McInerney, E., Westin, S., Thanos, D., Rosenfeld, M.G., Glass, C.K., Collins, T. Mol. Cell. Biol. (1999) [Pubmed]
  23. Reduction of chromatin assembly factor 1 p60 and C21orf2 protein, encoded on chromosome 21, in Down syndrome brain. Shim, K.S., Bergelson, J.M., Furuse, M., Ovod, V., Krude, T., Lubec, G. J. Neural Transm. Suppl. (2003) [Pubmed]
  24. Regulation of PCNA and CAF-1 expression by the two tuberous sclerosis gene products. Hengstschläger, M., Rosner, M., Fountoulakis, M., Lubec, G. Biochem. Biophys. Res. Commun. (2003) [Pubmed]
  25. Separation of Crotalus atrox (western diamondback rattlesnake) alpha-proteinase from serine proteinase and hemorrhagic factor activities. Kruzel, M., Kress, L.F. Anal. Biochem. (1985) [Pubmed]
  26. Purification, properties and alternate substrate specificities of arginase from two different sources: Vigna catjang cotyledon and buffalo liver. Dabir, S., Dabir, P., Somvanshi, B. Int. J. Biol. Sci. (2005) [Pubmed]
  27. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors. Cummings, F.J., Gelman, R., Horton, J. J. Clin. Oncol. (1985) [Pubmed]
  28. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). Davidson, N.E., O'Neill, A.M., Vukov, A.M., Osborne, C.K., Martino, S., White, D.R., Abeloff, M.D. J. Clin. Oncol. (2005) [Pubmed]
 
WikiGenes - Universities